Fetal tissue transplantation in Parkinson's disease

1993 ◽  
Vol 2 (20) ◽  
pp. 1012-1016 ◽  
Author(s):  
Louise Bain
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Fetal Tissue ◽  
Tissue Transplantation ◽  
Fetal Tissue Transplantation

Infectious disease issues in fetal tissue transplantation for Parkinson's disease

1993 ◽  
Vol 12 (9) ◽  
pp. 65-67
Author(s):  
Margarita Cancio ◽  
Thomas Rushton ◽  
Thomas B. Freeman ◽  
C.W. Olanow ◽  
John S. Sarzier ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Fetal Tissue ◽  
Tissue Transplantation ◽  
Fetal Tissue Transplantation

Outcomes and Complications of Fetal Tissue Transplantation in Parkinson’s Disease

1999 ◽  
Vol 72 (2-4) ◽  
pp. 219-224 ◽  
Author(s):  
Deane B. Jacques ◽  
Oleg V. Kopyov ◽  
Kaaren S. Eagle ◽  
Thomas Carter ◽  
Abraham Lieberman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Fetal Tissue ◽  
Tissue Transplantation ◽  
Fetal Tissue Transplantation

scholarly journals Informed Consent and Sham Surgery as a Placebo in Fetal Cell Transplant Therapy Research for Parkinson’s Disease

2016 ◽  
Vol 20 (1) ◽  
pp. 14
Author(s):  
Joshua David Rosenberg
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Informed Consent ◽  
Fetal Tissue ◽  
Control Group ◽  
Cell Transplant ◽  
Research Subjects ◽  
Double Blind ◽  
Sham Surgery ◽  
Fetal Tissue Transplantation

Fetal cellular transplantation therapy research in Parkinson’s Disease has raised important ethical questions from its beginning. One of the most hotly debated aspects of the recent clinical research has been the use of sham surgery as a placebo for the control group. Ethicists and researchers have focused on the unique risk surgical placebos pose to research subjects as compared to conventional, medical placebos. This review will deal with informed consent and the use of use of sham surgery in the placebo arm of recent fetal tissue transplantation randomized, placebo controlled, double blind, clinical trials. Do current procedures for obtaining informed consent meet the challenge of adequately informing patients enrolling in experiments with significant risks not only in the experimental group but also in the placebo group?

Neural Tissue Xenotransplantation: What is Needed Prior to Clinical Trials in Parkinson's Disease?

2000 ◽  
Vol 9 (2) ◽  
pp. 235-246 ◽  
Author(s):  
Roger A. Barker ◽  
A. Lisa Kendall ◽  
Håkan Widner ◽  
H. Widner ◽  
L. Larsson ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Human Tissue ◽  
Neural Tissue ◽  
Fetal Tissue ◽  
Suitable Material ◽  
Human Fetal Tissue ◽  
Critical Issues ◽  
Alternative Sources

Embryonic allografted human tissue in patients with Parkinson's disease has been shown to survive and ameliorate many of the symptoms of this disease. Despite this success, the practical problems of using this tissue coupled to the ethical restrictions of using aborted human fetal tissue have lead to an exploration for alternative sources of suitable material for grafting, including xenogeneic embryonic dopaminergic-rich neural tissue. Nevertheless, xenografted neural tissue itself generates a number of practical, ethical, safety, and immunological issues that have to be addressed prior to any clinical xenotransplant program. In this article we review these critical issues and set out the criteria that we consider need to be met in the development of our clinical xenotransplantation research programs. We advocate that these, or similar, criteria should be adopted and made explicit by other centers contemplating similar clinical trials.

Sign in / Sign up

Export Citation Format

Share Document